Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.05%||179.54||0.7%||$1296.44m|
|BMY||Bristol-Myers Squibb Co.||0.45%||77.59||1.0%||$1212.16m|
|MRK||Merck & Co., Inc.||-1.53%||92.32||0.7%||$1167.02m|
|LLY||Eli Lilly & Co.||2.11%||313.48||1.1%||$967.28m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.29%||142.98||0.0%||$491.89m|
|HZNP||Horizon Therapeutics Plc||2.45%||90.59||5.4%||$196.03m|
|NVO||Novo Nordisk A/S||1.30%||106.62||0.1%||$182.89m|
Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.